Your Sorted CME/CE Activities

Quarterly Brief (July-September 2021): A Current Expert Analysis on Important HIV Clinical Decisions
AMA/ANCC/ACPE Activities
New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of new agents, changing regimen strategies and development of long-acting novel agents. This expanding era of simplified and effective HIV therapy presents physicians with many new opportunities and challenges for providing care. To deliver state-of-the-art HIV prevention and care, healthcare providers must stay informed regularly of new clinical data and treatment recommendations in HIV.

This educational Quarterly Brief, covering HIV data from July through September of 2021 will discuss the most clinically relevant information including HIV prevention, novel agents, and ART considerations such as durability, metabolic effects and switching therapies.

Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
 









Faculty Chair
Paul Sax, MD Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Faculty
Raphael Landovitz, MD, MSc Raphael Landovitz, MD, MSc
Professor of Medicine
UCLA Center for Clinical AIDS Research & Education
UCLA Center for HIV Identification, Prevention, and Treatment Services
 

20
Supported by an independent educational grant from ViiV Healthcare

Launch Date: October 20, 2021
Release Date: October 20, 2021
Expiration Date: September 30, 2022

September 30, 2022
Mini Module
7246
QuarterlyBrief_WebBanner_1158.gif
HIV